Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.58 |
| ▸ | DDO | Q99489 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634876 | 1.00 | CA2 (0.61) | CA2DAODDOBRD4CA1 | |
| SCHEMBL829945 | 0.85 | DAO (0.56) | CA2DAODDOBRD4CA1 | |
| SCHEMBL27508522 | 0.84 | DAO (0.59) | CA2DAODDOBRD4KDR | |
| SCHEMBL2633970 | 0.82 | BRD4 (0.53) | CA2DAODDOBRD4CA1 | |
| SCHEMBL830554 | 0.81 | BRD4 (0.51) | CA2DAODDOBRD4KDR | |
| SCHEMBL32895 | 0.76 | CA2 (1.00) | CA2DAODDOCA1CA9 | |
| SCHEMBL32681985 | 0.76 | CA2 (1.00) | CA2DAODDOCA1CA9 | |
| Sulfuric Acid SCHEMBL1467316 | 0.75 | DAO (0.86) | CA2DAODDOBRD4KDR | |
| SCHEMBL15428777 | 0.74 | CA2 (0.58) | CA2CA1CA9CA12LMNA | |
| SCHEMBL545302 | 0.73 | DAO (0.60) | CA2DAODDOBRD4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255992-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-08-17 | — | — | US | disclosed |
| US-11628179-B2 | Compounds for treating and preventing extracellular histone mediated pathologies | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-04-18 | — | — | US | disclosed |
| US-20220168327-A1 | Compounds for Treating and Preventing Net Associated Complications | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2022-06-02 | — | — | US | disclosed |
| EP-3930726-A1 | COMPOUNDS FOR TREATING AND PREVENTING NET ASSOCIATED COMPLICATIONS | The Australian National University (AU) | 2022-01-05 | — | — | EP | disclosed |
| EP-3888094-A1 | METHOD FOR DETECTING AND MONITORING THE FORMATION OF BIOFILMS | Biofilm Control (FR) | 2021-10-06 | — | — | EP | disclosed |
| US-20210205343-A1 | Compounds for Treating and Preventing Extracellular Histone Mediated Pathologies | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2021-07-08 | — | — | US | disclosed |
| EP-3723768-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | The Australian National University (AU) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019113645-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2019-06-20 | — | — | WO | disclosed |
| US-9226939-B2 | Histone inhibition | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2016-01-05 | — | — | US | disclosed |
| US-20130338097-A1 | HISTONE INHIBITION | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2013-12-19 | — | — | US | disclosed |
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | disclosed |
| US-4867781-A | PRE- AND POSTEMERGENCE HERBICIDES; NONPHYTOTOXIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0107979-B1 | NOVEL PHENYL-SUBSTITUTED SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-10-12 | — | — | EP | disclosed |
| US-4741761-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-05-03 | — | — | US | disclosed |
| US-4620870-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4586950-A | HERBICIDES | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| EP-0107979-A1 | Novel phenyl-substituted sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628179-B2 | Compounds for treating and preventing extracellular histone mediated pathologies | HMGB1, HDAC2, H1-3 | CA2 1603/4885DAO 2602/4885DDO 1934/4885 |
| US-20220168327-A1 | Compounds for Treating and Preventing Net Associated Complications | HMGB1, MPO, MIF | CA2 1219/4885DAO 1260/4885DDO 862/4885 |
| US-20130338097-A1 | HISTONE INHIBITION | H1-5, H1-3, H1-2 | CA2 2445/4885DAO 2997/4885DDO 2989/4885 |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | CA2 2552/4885DAO 3359/4885DDO 1479/4885 |
| US-20210205343-A1 | Compounds for Treating and Preventing Extracellular Histone Mediated Pathologies | HMGB1, HDAC2, H1-3 | CA2 1603/4885DAO 2602/4885DDO 1934/4885 |
| US-20230255992-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | HMGB1, HDAC2, H1-3 | CA2 1565/4885DAO 814/4885DDO 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.